A specific tRNA half, 5’tiRNA-His-GTG, responds to hypoxia via the HIF1α/ANG axis and promotes colorectal cancer progression by regulating LATS2

En-Wei Tao1†, Hao-Lian Wang1†, Wing Yin Cheng2, Qian-Qian Liu1, Ying-Xuan Chen1* and Qin-Yan Gao1*

Abstract

Background: Currently, tRNA-derived small RNAs (tsRNAs) are recognized as a novel and potential type of non-coding RNAs (ncRNAs), which participate in various cellular processes and play an essential role in cancer progression. However, tsRNAs involvement in colorectal cancer (CRC) progression remains unclear.

Methods: Sequencing analyses were performed to explore the tsRNAs with differential expression in CRC. Gain- and loss-of functions of 5’tiRNA-His-GTG were performed in CRC cells and xenograft tumor to discover its role in the progression of CRC. Hypoxia culture and hypoxia inducible factor 1 subunit alpha (HIF1α) inhibitors were performed to uncover the biogenesis of 5’tiRNA-His-GTG. The regulation of 5’tiRNA-His-GTG for large tumor suppressor kinase 2 (LATS2) were identified by luciferase reporter assay, western blot, and rescue experiments.

Results: Here, our study uncovered the profile of tsRNAs in human CRC tissues and confirmed a specific tRNA half, 5’tiRNA-His-GTG, is upregulated in CRC tissues. Then, in vitro and in vivo experiments revealed the oncogenic role of 5’tiRNA-His-GTG in CRC and found that targeting 5’tiRNA-His-GTG can induce cell apoptosis. Mechanistically, the generation of 5’tiRNA-His-GTG seems to be a responsive process of tumor hypoxic microenvironment, and it is regulated via the HIF1α/angiogenin (ANG) axis. Remarkably, LATS2 was found to be an important and major target of 5’tiRNA-His-GTG, which renders 5’tiRNA-His-GTG to “turn off” hippo signaling pathway and finally promotes the expression of pro-proliferation and anti-apoptosis related genes.

Conclusions: In summary, the findings revealed a specific 5’tiRNA-His-GTG-engaged pathway in CRC progression and provided clues to design a novel therapeutic target in CRC.

Keywords: Colorectal cancer, Hypoxia, LATS2, Hippo signaling pathway, tRNA half
Highlights

1. 5′tRNA-His-GTG is a novel small non-coding RNA that promotes CRC progression
2. 5′tRNA-His-GTG is mainly located in cytoplasm and regulated via hypoxia/HIF1α/ANG axis
3. 5′tRNA-His-GTG inhibits the translation of LATS2 and suppresses the hippo signaling pathway
4. Suggested a new mechanism of 5′tRNA-His-GTG-engaged pathway in CRC progression

Background

Colorectal cancer (CRC) is one of the most common cancers and is the second leading cause of cancer-related death globally [1, 2]. Currently, the treatment options for CRC are mainly surgical resection and chemotherapy. Research efforts in recent decades have led to reductions in the incidence and mortality of CRC in adults over the age of 50 [3]. However, the low survival rate of patients with advanced CRC indicates that more effective treatments are required [4, 5]. In this regard, the pathological mechanisms driving CRC should be thoroughly investigated to identify novel biomarkers or therapeutic targets.

For decades, non-coding RNAs (ncRNAs) have been shown to play critical roles in both cellular function and human disease. The emerging roles of ncRNAs in cancer development have also been well discovered. Some ncRNAs are stable and detectable in various human biofluids, which can be regarded as potential non-invasive biomarkers in cancers [6]. Advances in oligonucleotide drug delivery make it more available to target ncRNAs against malignant tumors [7].

To date, an explosion of studies have focused on microRNAs (miRNAs), long non-coding RNAs (lncRNAs), piwi-interacting RNA (piRNAs), and circular RNAs (circRNAs), however, researchers rarely concerned tRNA, which is an ancient and well-known adapter that carries amino acids to the ribosome. Intriguingly, recent studies have identified tRNA can be cleaved under stress conditions [8–10], and next-generational sequencing indicated that the cleaved tRNA products are not randomly degraded fragments [11], which implies the biological function of these fragments. In subsequent studies, these fragments derived from tRNA were found to be implicated in various cellular processes, including stress response, ribosome biogenesis, epigenetic regulation, translational inhibition, and mRNA stability repression [12–14]. Thus, these fragments were gradually recognized as a novel class of small non-coding RNAs, named tRNA-derived small RNAs (tsRNAs). tsRNAs are classified into two major types: tRNA halves (30–45 nucleotides) and smaller tRNA fragments (tRFs) (14–30 nucleotides), based on their enzyme cleavage site and the length [15]. tRNA halves, also called tRNA-derived and stress-induced small RNAs (tiRNAs), are induced by stressors such as hypoxia, amino acid deficiency, UV radiation, heat shock, oxidative damage, and viral infection [14]. Regarding their specific biogenesis, current studies suggest that mature tiRNAs are cleaved by angiogenin (ANG) in the anticodon-loop region, generating 5′tiRNAs (30–35 nucleotides) and 3′tiRNAs (40–45 nucleotides) [8, 9, 16]. As for tRFs, they have three subclasses: 5′tRFs, 3′tRFs, i-tRFs. However, the biogenesis mechanism of tRFs remains unknown, it may be related to Dicer cleavage in D-loop or T-loop [17–19].

Both subtypes of tsRNA are closely related to the development of tumors [14, 20, 21]. For example, specific tRFs derived from tRNA-Glu, tRNA-Asp, tRNA-Gly, and tRNA-Tyr suppress breast cancer by binding to Y box binding protein 1 (YBX1) and destabilizing oncogenic transcripts [22]. One specific tRF, derived from tRNA-Leu, was identified as a regulator of ribosome biogenesis and is a potential target to treat cancer [23]. Besides, researchers also revealed that the sex hormone signaling pathway promotes angiogenin-mediated cleavage of mature tRNA and generates several 5′tiRNAs to enhance cell proliferation of breast and prostate cancers [24]. More recently, a novel tRF half named 5′tRNA-Val was found to suppress breast cancer cell’s proliferation, migration, and invasion via inhibiting the FZD3/Wnt/β-Catenin signaling pathway [25].

Despite the emerging interest in tsRNAs, the biogenesis and mechanism of tsRNAs remain largely unknown. In the present study, we identified that 5′tRNA-His-GTG plays an oncogenic role in CRC progression. Regulated by the hypoxia inducible factor 1 subunit alpha (HIF1α)/ANG axis, 5′tRNA-His-GTG interacts with large tumor suppressor kinase 2 (LATS2) to suppress hippo signaling. Strategies to disrupt the 5′tRNA-His-GTG-engaged pathway might be developed for treatment of colorectal cancer.

Materials and methods

CRC samples

We obtained 25 paired CRC tissues and adjacent normal tissues from Ren-ji Hospital, Shanghai Jiao-Tong University School of Medicine (Shanghai, China). Patients were diagnosed clinically and pathologically with colorectal cancer (the clinical information for the patients is listed in Table S1). None of the patients had received radiotherapy or chemotherapy before surgery. Written informed consent was obtained from each study patient. The study protocol was approved by the ethics committee of Shanghai Jiao-Tong University School of Medicine (Shanghai, China). All the research was carried out in...
ial Institute (RPMI) 1640 or Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Gibco, USA). To induce hypoxia, cells were incubated with 1% O₂, 5% CO₂, and 94% N₂ in a hypoxia chamber (YCP-50s; Huaxi Electronic Technology, Changsha, China).

**RNA extraction and quantitative real-time reverse transcription PCR**

Total RNA was extracted from cells and tissues using the Trizol reagent (Life Technologies, USA). A Cytoplasmic and Nuclear RNA Purification Kit (Norgen, Canada) was used to separate RNA from the cytoplasm and nucleus. RNA Pretreatment Kit (#: AS-FS-005, Arraystar, USA) and rtStar™ First-Strand cDNA Synthesis Kit (#: AS-FS-003, Arraystar, USA) were used to build specific cDNA libraries for the quantification of tsRNA in tissues. mRNA and 5’tiRNA-His-GTG were reverse transcribed to cDNA using a PrimeScript RT Reagent Kit (Perfect Real-Time, Takara, Japan) and a Bulge-Loop miRNA qRT-PCR Starter Kit (Ribobio, Guangzhou, China) in cells, respectively. Mature tRNA-His-GTG was reverse transcribed to cDNA using rtStar™ tRNA-optimized First-Strand cDNA Synthesis Kit (#: AS-FS-004, Arraystar). Then, qPCR was performed with SYBR Premix Ex Taq (Takara). The expression levels of tsRNAs and tRNA-His-GTG were normalized to that of U6, and the expression levels of miRNAs were normalized to that of β-actin. The primer used for detecting tRNA-His-GTG was purchased from Arraystar (#: AS-NR-001H-1-074), and the details of the other primers are shown in Table S2.

**Cell transfection**

Cells were seeded into plates overnight before transfection. The synthetic single-strand mimic (5’tiRNA-His-GTG mimic, modified with 2’-O-Methyl (2’-O-Me), 50 nM), inhibitor (5’tiRNA-His-GTG inhibitor, modified with 2’-O-Me, 100 nM), and small interfering RNAs (siRNAs, 50 nM) against human ANG, LAT52, AG01, AG02, AG03, and AG04 were purchased from GenePharma Technology (Shanghai, China). The transient transfection of RNA oligonucleotides was performed using the DharmaFECT 1 siRNA transfection reagent (Thermo Scientific Dharmacon Inc., USA). All the plasmids were obtained from Generay Biotechnology (Shanghai, China) and were transfected into CRC cells using the FuGENE transfection reagent (Life Technologies, USA). The sequences of siRNAs and the details of the RNA oligonucleotides are listed in Table S3 and Table S4.

**Cell proliferation, colony formation, and apoptosis assays**

Cell proliferation was determined by using a Cell Counting Kit 8 (CCK8) (Dojindo, Japan) according to the manufacturer’s instructions. Treated cells were seeded in 96-well plates at an initial density of 1500 cells (HCT116) or 2000 cells (LoVo, RKO) per well. For the colony formation assay, transfected cells (750–1000 cells per well) were cultured in 6-well plates for 8–10 days, and then fixed with 4% formaldehyde and stained using
0.1% crystal violet. The relative colony formation ability was determined using ImageJ (NIH, USA). The cell apoptosis assay was performed by using an Annexin V-fluorescein isothiocyanate (FITC) Apoptosis Detection Kit I (BD Biosciences, USA). Terminal deoxynucleotidyl transferase nick-end-labeling (TUNEL) staining of tissue sections, used a TUNEL staining Kit (Keygen Biotech, Nanjing, China) according to the manufacturer’s instructions.

**Western blotting and chemical reagents**

Western blotting analysis was performed according to standard procedures. An anti-β-actin antibody (KC-5A08, Kang Cheng, China) was used as a reference control. The following antibodies were obtained from the indicated sources: Anti-HIF-1α (#: 36169), anti-cleaved-PARP (#: 5625), anti-cleaved-Caspase9 (#: 9505), anti-PARP (#: 9532), anti-Caspase9 (#: 9502), anti-LATS2 (#: 5888), anti-Phospho-YAP-S127 (#: 13008), and anti-YAP (#: 14074) were obtained from Cell Signaling Technology (USA). Anti-ANG (#: ab10600) was obtained from Abcam (UK). The HIF-1α inhibitors LW6 (#: CSN20474) and 2-ME (#: CSN19253) were purchased from CSNpharm (USA).

**Luciferase assay**

Dual-luciferase reporter assays were used to evaluate the direct binding between HIF-1α and the ANG promoter region, as well as the 3′ untranslated region (UTR) region of LATS2 and 5′tiRNA-His-GTG mimic. The sequence of the ANG promoter was cloned into vector pGL3-basic. The pGL3-ANG and RLuc plasmids were co-transfected into HCT116 cells, treated with a HIF-1α inhibitor and DMSO, respectively, and cultured in a hypoxia chamber. The 3′UTR sequence of LATS2 was cloned into vector pmirGLO-basic. The negative control (NC) mimic or 5′tiRNA-His-GTG mimic were co-transfected with the wild-type or mutant vectors. After 48 h, the cells were harvested, and a luciferase assay was performed according to the manufacturer’s protocol (Promega, Madison, WI, USA). The relative value of luciferase was detected using a FLUOstar Omega (BMG LABTECH, Germany) and normalized to the value of Renilla luciferase activity.

**Immunofluorescence assay**

Cells were grown on a chamber slide, cultured in normoxia or hypoxia chambers separately for 48 h, fixed with 4% paraformaldehyde, permeated with 0.3% Triton X-100, and blocked with 1% bovine serum albumin (BSA). The cells were then incubated with primary antibodies (ANG, 1:500, Abcam) and secondary antibodies (Alexa Fluor 488, 1:400, Thermo Fisher Scientific) according to the manufacturer’s protocol. Finally, the cell nuclei were counterstained using-(4-aminophenyl)-1H-indole-6-carboxamidine (DAPI). The images were collected using a fluorescent microscope (Zeiss, Germany).

**Xenograft assay**

All animal experiments were performed in strict accordance with institutional guidelines and approved by the Institutional Animal Care and Use Committee of the Shanghai Research Center for Model Organisms Inc.; the IACUC permit number was 2019–0023. An antagomir is an RNA oligonucleotide with specific modifications suitable for in vivo experiments, and we confirmed that the 5′tiRNA-His-GTG antagomir performs the same function as the 5′tiRNA-His-GTG inhibitor in HCT116 cells (Fig. S3). Then, HCT116 cells (2.5 × 10⁶ in 100 μL phosphate-buffered saline (PBS)) were injected subcutaneously through the right axilla of 5-week-old male BALB/c nude mice (6 mice per group), which were purchased from VRL Animal Technology (Beijing, China). Six days after tumor cell inoculation, mice were randomly divided into five groups, including PBS, NC antagonist (5 nmol each), Scramble antagonist (5 nmol each), 5′tiRNA-His-GTG agomir (5 nmol each), and 5′tiRNA-His-GTG antagonim (5 nmol each). The five groups of mice were treated with RNA-oligos by way of multiple-center intratumor injection four times every 3 days. The tumor size was measured using calipers every 3 days. After 3 weeks, the mice were sacrificed, and xenografts were then collected for weight measurements and other experiments. The schematic diagram of the animal experiments is shown in Fig. S4.

**Northern blotting**

Northern blotting was performed to verify the results of qRT-PCR for 5′tiRNA-His-GTG and tRNA-His-GTG. The total RNA (20 μg) was separated by 15% urea polyacrylamide gels, then the separated gel was transferred onto the pre-wet Hybond-N+ nylon membrane (Millipore). The membrane was then UV-crosslinked at 1200 mJ in Stratagene UV Stratalinker 1800 (SCIENTZ03-II, Ningbo, China) and hybridized with DIG-labeled DNA probes (Sangon Biotech, Shanghai, China). The sequences of the northern probes are listed in Table S5.

**Statistical analysis**

All results were obtained from at least three independent experiments and are expressed as means ± SD. All analyses were performed using GraphPad Prism 7.0 (GraphPad Software, USA). A two-tailed Student’s t-test was used to compare normally distributed continuous variables between two groups. The relationship between 5′tiRNA-His-GTG and tumor size was determined using Pearson’s correlation coefficient. p < 0.05 was considered statistically significant.
Fig. 1 (See legend on next page.)
Fig. 1 5'tiRNA-His-GTG is overexpressed in CRC tissues and is associated with tumor size. 

a Volcano plot displaying differentially expressed tsRNAs between four pairs of CRC and corresponding normal tissues. 

b Hierarchical cluster heatmap of upregulated and downregulated tsRNAs. 

c The relative expression levels of 10 selected tsRNAs were examined in four pairs of CRC and corresponding normal tissues using qRT-PCR. 

d The expression of 5'tiRNA-His-GTG, 3'tiRNA-Ile-AAT, 3'tiRNA-Lys-CTT, and 3'tiRNA-Arg-TCT-2-1 in 25 pairs of tissues were determined using qRT-PCR. 

e Paired comparison of 5'tiRNA-His-GTG expression levels between CRC and corresponding normal tissue (cancer-normal). 

f 5'tiRNA-His-GTG was highly expressed in larger tumors (left) and correlated positively with tumor size (right). *p < 0.05, **p < 0.01. All data are representative of at least three independent experiments and are presented as the means ± SD. 
CRC, colorectal cancer; tsRNA, tRNA-derived small RNA; qRT-PCR, quantitative real-time reverse transcription PCR.

Fig. 2 Characteristics and detection methods of 5'tiRNA-His-GTG. 

a tsRNAs are mainly divided into five types: i-tRF, 3'-tRF, 5'-tRF, 3'-tiRNA, and 5'-tiRNA. 

b 5'tiRNA-His-GTG was derived from mature tRNA-His-GTG with a length of 35 nt. 

c 5'tiRNA-His-GTG is mainly located in the cytoplasm, as assessed using a nuclear-cytoplasmic fractionation assay. 

d Schematic diagram of the two methods for detecting 5'tiRNA-His-GTG. 

(e) Relative expression level of 5'tiRNA-His-GTG with and without RNA pre-treatment using the Stem-loop RT method. 

f The product of qRT-PCR was confirmed by Sanger Sequencing. All data are representative of at least three independent experiments and are presented as the means ± SD. tsRNA, tRNA-derived small RNA; tRF, tRNA-derived fragment; tiRNA, tRNA-derived and stress-induced small RNA; qRT-PCR, quantitative real-time reverse transcription PCR.
Fig. 3 (See legend on next page.)
Results

5’tiRNA-His-GTG is upregulated in human CRC tissues and is associated with tumor size

To identify essential tsRNAs expressed in CRC tissues, four pairs of CRC and corresponding normal tissues were selected for next-generation sequencing analysis. Dysregulation of tsRNAs were observed in CRC tissues (fold change ≥ 2 or < 0.5 and p-value < 0.05), with 39 upregulated tsRNAs and 18 downregulated tsRNAs (Fig. 1a, b). We then selected 10 of them for further qRT-PCR validation. The results showed that 5’tiRNA-His-GTG, 3’tiRNA-Ile-AAT, 3’tiRNA-Lys-CTT, and 3’tiRNA-Arg-TCT-2-1 were upregulated in CRC tissues (Fig. 1c). An additional 21 pairs of CRC and corresponding normal tissues were analyzed using qRT-PCR, which confirmed the above findings (Fig. 1d). Notably, the expression level of 5’tiRNA-His-GTG was the highest and upregulated by 3.5-fold in tumor tissues (Fig. 1e); besides, 5’tiRNAs have been reported to be more biologically significant compared with 3’tiRNAs [26, 27], and to play roles in tumor development [28]. Therefore, we focused on 5’tiRNA-His-GTG, which we considered to be an important tsRNA in the development of CRC, for further research. Moreover, we found that 5’tiRNA-His-GTG correlated positively with tumor size (Fig. 1f), but not with age, sex, or clinical stage (Fig. S1).

Characteristics and detection methods of 5’tiRNA-His-GTG

Currently, tsRNAs are classified into two major types: tiRNAs (5’tiRNAs and 3’tiRNAs) and tRFs (5’tRFs, 3’tRFs, and 1’tRFs), based on their enzyme cleavage sites (Fig. 2a). 5’tiRNA-His-GTG, derived from the half of mature tRNA-His-GTG, is a 5’tiRNA with a length of 35 nucleotides (Fig. 2b). To determine the intracellular location of 5’tiRNA-His-GTG, a nuclear-cytoplasmic fractionation assay was used to separate RNA from the cytoplasm and nucleus. qRT-PCR analysis showed that 5’tiRNA-His-GTG was mainly located in the cytoplasm in the indicated CRC cell lines (Fig. 2c).

tsRNAs are heavily decorated by RNA modifications that interfere with cDNA synthesis, and many tsRNAs share the same base sequence; therefore, the current detection method for tsRNAs requires additional demodification and 3’/5’-adaptor ligation (Fig. 2d, left). However, 5’tiRNA-His-GTG only needed 3’-adaptor ligation, so we decided to adopt a simplified cDNA synthesis method called Stem-loop RT PCR (Fig. 2d, right). Moreover, we also found that RNA pre-treatment was not necessary to detect 5’tiRNA-His-GTG using the Stem-loop RT method (Fig. 2e). Finally, we performed the Sanger sequencing of the PCR products of qRT-PCR and Stem-loop RT PCR, and the sequences matched perfectly (Fig. 2f, Fig. S2). Northern blot also proved this simple method to detect 5’tiRNA-His-GTG is accurate (Fig. S11b, d).

5’tiRNA-His-GTG plays an oncogenic role in CRC

The expression levels of 5’tiRNA-His-GTG in different CRC cell lines (RKO, SW1116, LoVo, Caco2, SW480, HCT116, and DLD1) were determined using qRT-PCR, and the results showed that 5’tiRNA-His-GTG is highly expressed in HCT116 and LoVo cells, and weakly in RKO cells (Fig. 3a). Inhibition and upregulation of 5’tiRNA-His-GTG in HCT116, LoVo, and RKO cells (the transfection efficiency is shown in Fig. S5a) were performed to explore the effect of 5’tiRNA-His-GTG on CRC cell proliferation. The results showed that transfection of 5’tiRNA-His-GTG mimic promoted cancer cell proliferation, while suppression of 5’tiRNA-His-GTG significantly inhibited cancer cell growth (Fig. 3b). Moreover, inhibition of 5’tiRNA-His-GTG markedly reduced colony formation (Fig. 3c, Fig. S6a) and induced apoptosis in the indicated cells (Fig. 3d, Fig. S6b). The induction of apoptosis was confirmed using western blotting. The levels of cleaved-poly (ADP-Ribose) polymerase 1 (PARP) and cleaved-Caspase 9 were upregulated after 5’tiRNA-His-GTG inhibition, while the levels of PARP and Caspase 9 were downregulated (Fig. 3e, Fig. S6c). Furthermore, to address the role of 5’tiRNA-His-GTG in vivo, 2.5 × 10^6 HCT116 cells were injected into the right axilla subcutaneous tissues of nude mice. 6 days after inoculation, the tumors were treated with PBS, NC antagonir, Scramble antagonir, 5’tiRNA-His-GTG agonir, or 5’tiRNA-His-GTG antagonir via multiple-center...
Fig. 4 (See legend on next page.)
intratumor injection five times every 3 days. Tumor growth was measured every 3 days and tumors were dissected at the end of the experiment. The size of the tumor in the 5′tiRNA-His-GTG agomir group was larger than that in other control groups, and the results of tumor growth and tumor weights showed that the 5′tiRNA-His-GTG agomir could increase the formation and growth of the transplanted tumors, while the 5′tiRNA-His-GTG antagonir had the opposite effect (Fig. 3f-h). Moreover, the 5′tiRNA-His-GTG antagonist could induce apoptosis, which was confirmed using a TUNEL assay (Fig. 3i). These results indicated that 5′tiRNA-His-GTG plays an oncogenic role in CRC progression.

5′tiRNA-His-GTG is regulated via the hypoxia/HIF1α/ANG axis

The sustained rapid growth of cancer cells can outstrip the supply of nutrients and oxygen, creating a hypoxic environment [29], and a previous study showed that tiRNAs were induced under hypoxic conditions [30]. This might explain why 5′tiRNA-His-GTG is upregulated in tumor tissues and correlated positively with tumor size. To further explore this aspect, we cultured CRC cells in an anoxic incubator. The level of the HIF1α protein was significantly increased after 6 h of hypoxia in the indicated cells (Fig. 4a). Next, the expression levels of 5′tiRNA-His-GTG under hypoxic conditions were assessed and the result showed 5′tiRNA-His-GTG was upregulated with prolonged hypoxia time (Fig. 4c). ANG, which correlates closely with the production of tiRNAs [9], was determined in CRC cell lines under hypoxia. Notably, the protein (Fig. 4b) and mRNA levels (Fig. S5b) of ANG were increased under hypoxia. To further investigate the relationship between ANG and 5′tiRNA-His-GTG, an siRNA was used to knockdown ANG (the knockdown efficiency is shown in Fig. 4d and Fig. S5c) expression in cells cultured in the hypoxic environment. The expression level of 5′tiRNA-His-GTG decreased upon ANG depletion (Fig. 4d). Moreover, we found that HIF1α inhibitors (LW6 (10 µM) and 2-ME (10 µM)) suppressed both hypoxia-induced ANG and 5′tiRNA-His-GTG expression (Fig. S5d, Fig. 4e), which suggested that HIF1α was a critical upstream regulator of hypoxia-induced 5′tiRNA-His-GTG. Immunofluorescence analysis showed that ANG was upregulated under hypoxic conditions and is mainly located in the cytoplasm of the indicated cells, as shown using immunofluorescence (IF). The binding sites of HIF1α to the ANG promoter were obtained from JASPAR. A luciferase reporter assay was used to measure the direct binding between HIF-1α and the ANG promoter region under a hypoxic environment. *p < 0.05, **p < 0.01, ns: not significant. All data are representative of at least three independent experiments and are presented as the means ± SD. ANG, angiogenin; HIF-1α, hypoxia inducible factor 1 subunit alpha; qRT-PCR, quantitative real-time reverse transcription PCR.

5′tiRNA-His-GTG directly targets LATS2 and inhibits hippo signaling pathway

We next investigated the molecular mechanism associated with 5′tiRNA-His-GTG in the progression of CRC. According to the principle of complementary base pairing, we used TargetScan and miRanda prediction tools to identify 10 potential target genes that are most likely to bind to 5′tiRNA-His-GTG (Table S6, Fig. 5a). To confirm the predicted target genes, 5′tiRNA-His-GTG mimics were transfected into the indicated cells, and after 48 h, the mRNA expression in the cells was analyzed using qRT-PCR. Among the 10 target genes, the expression levels of LAT2 mRNA were decreased in both HCT116 and LoVo cells overexpressing 5′tiRNA-His-GTG (Fig. 5b). LAT2, a key component of the tumor-suppressive hippo signaling pathway, inhibits proliferation and promotes apoptosis by regulating yes-associated protein (YAP) activity [31, 32]. Therefore, the protein levels of LAT2, phosphorylated (phospho)-YAP (Ser127), and total YAP in the presence of 5′tiRNA-His-GTG mimics or inhibitors were detected. The results of western blotting revealed that the 5′tiRNA-His-GTG mimic significantly decreased the levels of LAT2 and phospho-YAP (Ser127), but increased the level of total YAP (Fig. 5c). In the xenograft mouse models, we also
Fig. 5 (See legend on next page.)
found that the level of LATS2 and phospho-YAP (Ser127) was decreased in the 5’tiRNA-His-GTG agomir group, while the level of total YAP was increased (Fig. S8). Considering that cell density might affect the expression of LATS2 [33], we examined the level of the LATS2 protein at different cell densities and found that high cell density increased the level of LATS2 (Fig. S9a). Therefore, the effect of 5’tiRNA-His-GTG mimic or inhibitor on the LATS2 protein is not caused by its effect on cell density. Besides, we found that hypoxic treatment decreased the expression of LATS2 (Fig. S9b) and reduced 5’tiRNA-His-GTG inhibition-mediated suppressive effects on CRC cells (Fig. S10a), and 5’tiRNA-His-GTG inhibitor attenuated hypoxia-induced YAP activation (Fig. S10b), indicating a close relationship between 5’tiRNA-His-GTG and LATS2 under hypoxia. To further demonstrate the impact of 5’tiRNA-His-GTG on the hippo signaling pathway, we validated 10 downstream genes of the hippo signaling pathway using qRT-PCR. The results indicated that 5’tiRNA-His-GTG affected many hippo signaling pathway-related genes such as CTGF, BIRC5, and CCND1 (Fig. 5d). Target prediction programs indicated that there were potential specific targets for 5’tiRNA-His-GTG in the seed regions within the 3’UTR of LATS2 (Fig. 5e). The empty vector, reporter vector pmirGLO carrying the LATS2 3’UTR, and the LATS2 3’UTR mutant vector were co-transfected with 5’tiRNA-His-GTG mimics or negative control into HCT116 cells. After 48 h, the cells were collected for luciferase detection. The results suggested that 5’tiRNA-His-GTG reduced the relative luciferase activity significantly when co-transfected with the pmirGLO-LATS2 compared with pmirGLO-basic or pmirGLO-mut (Fig. 5f). Previous studies have shown that argonaute (AGO) family proteins associate with tsRNAs and are involved in the regulation of gene expression [34, 35]. Therefore, we knocked down AGO1, AGO2, AGO3, and AGO4 expression (Fig. S5e) and observed changes in luciferase expression. Luciferase expression inhibited by 5’tiRNA-His-GTG was reverted by the silencing of AGO1 and AGO3 (Fig. 5g). These results indicated AGO1 and AGO3 mediate 5’tiRNA-His-GTG regulation of LATS2 gene expression.

Attenuation of LATS2 partly rescues 5’tiRNA-His-GTG inhibition-mediated suppressive effects on CRC cells

We next knocked down LATS2 (the knockdown efficiency is shown in Fig. 6d and Fig. S5f) in 5’tiRNA-His-GTG-inhibited CRC cells and performed CCK8, colony formation, and apoptosis assays to investigate whether 5’tiRNA-His-GTG plays an oncogenic role in CRC progression dependent on LATS2. The CCK8 assay showed increased cell proliferation in the Si-LATS2 / 5’tiRNA-His-GTG inhibitor group in HCT116 and LoVo cells compared with the Si-NC / 5’tiRNA-His-GTG inhibitor group, but did not reach the level of the Si-NC / NC inhibitor group (Fig. 6a). Knockdown of LATS2 could weaken the repressive effect of the 5’tiRNA-His-GTG inhibitor on colony formation (Fig. 6b), while it reduced the cell apoptosis induced by the 5’tiRNA-His-GTG inhibitor, as shown by FACS analysis (Fig. 6c). Knockdown of LATS2 also decreased YAP phosphorylation, but increased the total level of YAP (Fig. 6d), as assessed using western blotting. Meanwhile, certain downstream genes of the hippo signaling pathway were upregulated upon Si-LATS2 transfection in 5’tiRNA-His-GTG-inhibited CRC cells (Fig. 6e). Taken together, these data demonstrated that LATS2 is involved in the suppressive effects of 5’tiRNA-His-GTG inhibition on CRC cells; however, the role of 5’tiRNA-His-GTG in CRC is not completely dependent on LATS2.

Discussion

On the basis of our findings, we present a novel pathway (Fig. 6f) involved in the progression of CRC. In solid tumors, including CRC, sustaining rapid growth of cancer cells can outstrip the supply of nutrients and oxygen, creating a hypoxic environment. Hypoxia-induced HIF1α promotes the transcription of ANG, which in turn increases the cytoplasmic level of 5’tiRNA-His-GTG. Then, 5’tiRNA-His-GTG was found to “turn off” the hippo signaling pathway by inhibiting LATS2.
Fig. 6 (See legend on next page.)
translation. This discovery indicated that CRC cell might protect itself from the hypoxic environment by producing 5′tiRNA-His-GTG, which provides a new mechanism of CRC progression and updates strategies to control CRC.

tsRNAs, which were previously considered to be random degradation products of tRNAs, are now classified as an important class of functional small non-coding RNAs. However, our knowledge of tsRNAs is only the tip of the iceberg, there remain plentiful problems that need to be solved. For instance, the details of tsRNA generation are still largely unknown. Although previous studies showed that the production of tsRNAs is closely related to ANG [27, 36, 37], a recent study verified that the production of tiRNA-His-GTG is not completely dependent on ANG, suggesting there are other RNases that produce tiRNAs [38]. Moreover, mature tRNA has a lot of base modifications, such as m5C, m1A, m3C, and Ψ (Pseudouridylation), which can protect tRNA from cleavage [39–43]. It is also essential to understand the intrinsic and extrinsic factors that participate in the production of tsRNAs. While our results stress the hypothesis/ HIF1α/ANG axis has a great impact on mature tRNA-His-GTG cleavage, which suggested that the cancer cells produced more 5′tiRNA-His-GTG under the external stimulation of hypoxia. Second, the current method for detecting tsRNAs is complex. Northern blot has been regarded as the gold standard for detecting tsRNA, but the process is complicated, and it is not applicable for screening from numerous tsRNAs. As for next-sequencing and qRT-PCR, tsRNAs need to erase their modifications first, such as m1A, m1G, m3C, which can interfere with reverse transcription [44]. Nonetheless, our data showed that the relative expression level of 5′tiRNA-His-GTG was consistent between the treated and non-treated groups. This may be due to insufficient methylation modification on 5′tiRNA-His-GTG, which also indicates that not every tsRNA needs to be demethylated before reverse transcription. Third, the relationship between base modifications on tsRNA and its biological function is currently unclear. However, existing evidence suggests that synthetic tsRNA is less functional than endogenous tsRNA [45]. It also needs to be mentioned that many of tsRNAs derived from 5′ end of tRNA (tRNA-Ala/Cys/Val) containing a stretch of guanine residues, which will form G-quadruplex and play a biological function such as inhibiting translation [42, 46, 47]. There is no evidence that 5′tiRNA-His-GTG can form G-quadruplex. Four, based on their source and length, tsRNAs have a wide variety and possess various biological functions. It seems that tiRNAs competitively bind to translation-related proteins, thereby inhibiting translation [26, 47], while tRFs were proved to regulate target gene expression based on sequence complementarity like miRNA [18, 19, 48, 49]. More research is needed to reveal the inner nature of tsRNAs. Moreover, with the in-depth research on this kind of novel small non-coding RNAs, it is urgent to develop a systematic and unified naming method for tsRNAs.

In the present study, we sequenced four pairs of CRC and corresponding normal tissues to measure the global abundance of tsRNAs in CRC, which identified 39 up-regulated tsRNAs and 18 downregulated tsRNAs. Intriguingly, 5′tiRNA-His-GTG was significantly upregulated by 3.5-fold in CRC tissues and correlated positively with tumor size. 5′tiRNA-His-GTG is a specific tRNA half derived from mature tRNA-His-GTG and mainly located in the cytoplasm. Cell experiments showed that 5′tiRNA-His-GTG is highly expressed in HCT116 and LoVo cell lines and is essential for cancer cell proliferation. Blocking 5′tiRNA-His-GTG can induce cell apoptosis, and we excluded the effect of 5′tiRNA-His-GTG inhibitor on mature tRNA-His-GTG via qRT-PCR (Fig. S11a, c) and northern blotting (Fig. S11d). Then, a xenograft experiment was performed to confirm the above findings, which showed that delivery of an antagonim against 5′tiRNA-His-GTG reduced the tumor burden and promoted apoptosis in mice xenografts, while the 5′tiRNA-His-GTG agomir could promote tumor growth. These findings indicated that 5′tiRNA-His-GTG acts as a tumor promoter in the progression of CRC. Next, the upstream regulatory mechanism of 5′tiRNA-His-GTG and its relationship with tumor size were studied. Previous studies showed that the production of tiRNAs is closely related to ANG [27, 37, 50, 51], and ANG is up-regulated under hypoxic conditions [52, 53]. It is also
reported that ANG is upregulated in CRC tissues [37]. Thus, we suspect that the upregulation of 5’tiRNA-His-GTG in CRC tissues was probably caused by an increase in ANG in response to the hypoxic environment in tumor tissues. 5’tiRNA-His-GTG is mainly located in the cytoplasm, providing an important clue to its biological origin and function. Our results suggested that ANG induced the production of 5’tiRNA-His-GTG under hypoxia. In addition, we found that HIF1α, the well-known sensor for cells to respond to oxygen availability [54, 55], was also involved in the production of ANG and 5’tiRNA-His-GTG. Luciferase reporter assays suggested that HIF1α might bind to the promoter region of ANG and promote its transcription. Overall, we showed that 5’tiRNA-His-GTG is regulated via the hypoxia/HIF1α/ANG axis.

We further explored the mechanisms by which 5’tiRNA-His-GTG contributes to colorectal carcinogenesis. Current research suggests that tsRNAs are involved in various cellular processes, including translational reprogramming [27, 36], apoptosis suppression [56, 57], and gene silencing [19, 49]. Additionally, some tsRNAs are bound by AGO proteins, which might employ a miRNA-like mechanism to regulate gene expression [34, 35, 49, 58]. Thus, using TargetScan and miRanda prediction tools, LATS2 was selected as the potential target of 5’tiRNA-His-GTG. LATS2, a pivotal kinase of the hippo signaling pathway, ensures the spatial and temporal control of yes-associated protein (YAP) activity, while YAP recruits other factors to induce gene transcription [59]. We found 5’tiRNA-His-GTG could significantly decrease the level of the LATS2 protein, but only slightly downregulated the expression of the LATS2 mRNA. Moreover, the luciferase assay further revealed AGO1 and AGO3 mediate 5’tiRNA-His-GTG regulation of LATS2 expression. We hypothesized that 5’tiRNA-His-GTG could regulate the transcription of LATS2 rather than its transcription based on the following two points: 5’tiRNA-His-GTG has a special spatial structure (D-loop or some modifications) and cannot bind to the LATS2 mRNA; in the AGO protein family, only AGO2 has strong enzymatic cleavage activity. Finally, rescue experiments showed that attenuation of LATS2 partly rescues 5’tiRNA-His-GTG inhibition-mediated suppressive effects on CRC cells. This confirmed the role of LATS2 in 5’tiRNA-His-GTG-mediated carcinogenesis.

Our study also has several limitations. First, although we found that four tsRNAs were upregulated in CRC tissues, only 5’tiRNA-His-GTG was uncovered. The role of 3’tiRNA-Ile-AAT, 3’tiRNA-Lys-CTT, and 3’tiRNA-ArgTCT-2-1 need to be further studied. Second, ANG is well-known for promoting tumor angiogenesis under hypoxia [60], but it is reported that ANG-induced tsRNAs (derived from tRNA-Val-CAC and tRNA-Gly-GCC) act as negative regulators of angiogenesis in endothelial cells under hypoxia [61]. Considering that ANG can induce the generation of various tsRNAs, whether these various tsRNAs, including 5’tiRNA-His-GTG, play different roles in tumor angiogenesis requires further investigations. Third, 5’tiRNA-His-GTG is larger than miRNA, whether it can directly bind to AGO1/3 and be loaded into the RNA-induced silencing complex (RISC) need more explorations. Fourth, attenuation of LATS2 could not completely rescue 5’tiRNA-His-GTG inhibition-mediated suppressive effects on CRC cells, thus there remain other targets of 5’tiRNA-His-GTG, which may be related to the inhibition of translation initiation by 5’tiRNA [26]. Our research provides the basis for further in-depth studies of 5’tiRNA-His-GTG in CRC.

Conclusions

In conclusion, we identified 5’tiRNA-His-GTG as an oncogenic tRNA half in CRC and further uncovered a novel pathway in which hypoxia-induced 5’tiRNA-His-GTG suppresses LATS2, leading to CRC progression. Targeting 5’tiRNA-His-GTG or its associated network could represent novel therapies for patients with CRC.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13046-021-01830-7.

Additional file 1: Table S1. Clinical information for the patients included in this study. Table S2. Primers used for real-time PCR assay. Table S3. Small interfering RNA (siRNA) sequences. Table S4. RNA oligonucleotide sequences. Table S5. Northern blot probe sequences. Table S6. Predicted target genes of 5’tiRNA-His-GTG. Figure S1. Distribution of the 5’tiRNA-His-GTG relative expression level in different groups. (a) The expression level of 5’tiRNA-His-GTG showed no significant difference between early stage and advanced stage CRC. (b) There was no difference in the expression level of 5’tiRNA-His-GTG above and below the age of 60 years old. (c) The expression level of 5’tiRNA-His-GTG was not significantly different between males and females. ns: not significant. CRC, colorectal cancer. Figure S2. Sanger sequencing of the PCR products of 5’tiRNA-His-GTG. (a) 5’tiRNA-Lys-CTT. (b) 5’tiRNA-Arg-TCT-2-1. (c) 5’tiRNA-Ile-AAT. Figure S3. The 5’tiRNA-His-GTG antagomir performs the same function as 5’tiRNA-His-GTG inhibitor in HCT116 cells. Figure S4. Schematic diagram of animal experiments. Figure S5. qRT-PCR validation of different genes. Figure S6. 5’tiRNA-His-GTG inhibition reduces anchorage-dependent growth and induces apoptosis in RKO cells. Figure S7. LW6 and 2-ME have no effect on HIF-1α/ANG/5’tiRNA-His-GTG axis under normoxia in HCT116 cells. Figure S8. The expression level of LATS2, phospho-YAP (Ser127), and YAP in the xenograft tumors. Figure S9. The expression level of LATS2 upon different cell densities and various hypoxia time. Figure S10. The role of 5’tiRNA-His-GTG inhibitor under hypoxic environment. Figure S11. The expression level of 5’tiRNA-His-GTG in various groups using qRT-PCR and northern blot.

Abbreviations

AGO: Argonute; ANG: Angiogenin; CRC: Colorectal cancer; HIF1α: Hypoxia inducible factor 1 subunit alpha; LATS2: Large tumor suppressor kinase 2; ncRNAs: Non-coding RNAs; PARP: Cleaved poly (ADP-Ribose) polymerase 1; RISC: RNA-induced silencing complex; tiRNAs: tRNA-derived and stress-induced small RNAs; trfRs: tRNA fragments; tsRNAs: tRNA-derived small RNAs; YAP: Yes-associated protein; YBX1: Y box binding protein 1.
Acknowledgements
The authors are grateful to all the individuals who participated in the study.

Authors’ contributions
E. W. Tao, H. L. Wang, and Q. Q. Liu performed the experiments and analyzed the data. E. W. Tao drafted the manuscript. W. Y. Chong revised the manuscript critically. Q. Y. Gao and Y. X. Chen designed or/and supervised this project and revised the manuscript. The authors read and approved the final manuscript.

Funding
This study was supported in part by National Natural Science Foundation of China (Grant No: 81772506 and 81972203).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the ethics committee of Shanghai Jiao-Tong University School of Medicine (Shanghai, China). Written informed consent was obtained from all patients and data was analyzed anonymously. All the research was carried out in accordance with the provisions of the declaration of Helsinki of 1975. All Animal experiments complied with the national guidelines for the care and use of laboratory animals.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology & Hepatology, Ministry of Health, Ren-Ji Hospital, Shanghai Jiao-Tong University School of Medicine, Renji Hospital, 145 Middle Shandong Road, 200001 Shanghai, China. 2Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong 990077, China.

Received: 14 September 2020 Accepted: 10 January 2021
Published online: 15 February 2021

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jamal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jamal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
3. Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524–48.
4. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–502.
5. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Bari A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.
6. Slack FJ, Chininaiyan AM. The role of non-coding RNAs in oncology. Cell. 2019;179(5):1033–55.
7. Roberts TC, Langer R, Wood MJ. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673–94.
8. Fu H, Feng J, Liu Q, Sun F, Tie Y, Zhu J, et al. Stress induces tRNA cleavage by angiogenin in mammalian cells. FEBS Lett. 2009;583(2):437–42.
9. Thompson DM, Parker R. Stressing out over tRNA cleavage. Cell. 2009;138(2):215–9.
10. Thompson DM, Lu C, Green PJ, Parker R. tRNA cleavage is a conserved response to oxidative stress in eukaryotes. Rna. 2008;14(10):2095–103.
11. Zheng LL, Xu WL, Liu S, Sun WJ, Lu JH, Wu J, et al. tRF2Cancer: a web server to detect tRNA-derived small RNA fragments (tRFs) and their expression in multiple cancers. Nucleic Acids Res. 2016;44(W1):W185–93.
12. Anderson P, Ivanov P. tRNA expression post-transcriptionally in human disease. FEBS Lett. 2014;588(23):4297–304.
13. Zhu L, Liu X, Pu W, Peng Y. tRNA-derived small non-coding RNAs in human disease. Cancer Lett. 2018;419:1–7.
14. Li S, Xu Z, Sheng J. tRNA-Derived Small RNA: A Novel Regulatory Small Non-Coding RNA. Genes (Basel). 2018;5(3):246.
15. Lee YS, Shibata Y, Malhotra A, Dutta A. A novel class of small RNAs: tRNA-derived fragments. RFS. Genes Dev. 2009;23(2):2639–49.
16. Saikia M, Hatagolou M. The many virtues of tRNA-derived stress-induced RNAs (tRNAs): discovering novel mechanisms of stress response and effect on human health. J Biol Chem. 2015;290(50):29761–8.
17. Cole C, Sobala A, Lu C, Thatcher SR, Bowman A, Brown JW, et al. Filtering of deep sequencing data reveals the existence of abundant dicer-dependent small RNAs derived from tRNAs. Rna. 2009;15(12):2147–60.
18. Maute RJ, Schneider C, Sumaeg P, Holmes A, Calafano A, Basso K, et al. tRNA-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in B cell lymphoma. P Natl Acad Sci USA. 2013;110(4):1404–9.
19. Huang B, Yang H, Cheng X, Wang D, Fu S, Shen W, et al. tRF/miR-1280 suppresses stem cell-like cells and metastasis in colorectal Cancer. Cancer Res. 2017;77(12):3194–206.
20. Sun C, Fu Z, Wang S, Li J, Li Y, Zhang Y, et al. Roles of tRNA-derived fragments in human cancers. Cancer Lett. 2018;414:16–25.
21. Zeng T, Hua Y, Sun C, Zhang Y, Yang F, Yang M, et al. Relationship between tRNA-derived fragments and human cancers. Int J Cancer. 2020;147(11):3007–18.
22. Goodarzi H, Liu X, Nguyen HC, Zhang S, Fish L, Tavazoie SF. Endogenous tRNA-derived fragments suppress breast Cancer progression via YBX1 displacement. Cell. 2015;161(4):790–802.
23. Kim HK, Fuchs G, Wang S, Wei W, Zhang Y, Park H, et al. A transfer-RNA-derived small RNA regulates ribosome biogenesis. Nature. 2017;552(683):57–62.
24. Honda S, Loher P, Shigematsu M, Palazzo JP, Suzuki R, Imoto I, et al. Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers. Proc Natl Acad Sci U S A. 2015;112(29):E3816–25.
25. Mo D, Jiang P, Yang Y, Mao X, Tan X, Tang X, et al. A tRNA fragment, s'-tRNA (Val), suppresses the Wnt/beta-catenin signaling pathway by targeting FZD3 in breast cancer. Cancer Lett. 2019;457:60–73.
26. Ivanov P, Emam MM, Villen J, Gygi SP, Anderson P. Angiogenin-induced tRNA fragments inhibit translation initiation. Mol Cell. 2011;43(4):613–23.
27. Emam MM, Ivanov P, Hickman T, Dawa N, Tisdale S, Kedersha N, et al. Angiogenin-induced tRNA-derived stress-induced RNAs promote stress-induced stress granule assembly. J Biol Chem. 2010;285(14):10959–68.
28. Tao EW, Cheng WY, Li WL, Yu J, Gao QY. tRNAs: A novel class of small noncoding RNAs that helps cells respond to stressors and plays roles in cancer progression. J Cell Physiol. 2020;235(2):683–90.
29. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histogram. Antioxid Redox Signal. 2007;9(8):1221–35.
30. Cul Y, Huang Y, Wu X, Zheng M, Xia Y, Fu Z, et al. Hypoxia-induced tRNA-derived fragments, novel regulatory factor for doxorubicin resistance in triple-negative breast cancer. J Cell Physiol. 2019;234(6):8740–51.
31. Harvey KF, Zhang X, Thomas DM. The hippo pathway and human cancer. Nat Rev Cancer. 2013;13(4):246–57.
32. Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and Cancer. Cell. 2015;163(6):811–28.
33. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747–61.
34. Kumar P, Anaya J, Mudunuri SB, Dutta A. Meta-analysis of tRNA derived RNA fragments reveals that they are evolutionarily conserved and associate with AGO proteins to recognize specific RNA targets. BMC Biol. 2014;12:78.
35. Kuscu K, Kumar P, Kitam M, Su Z, Malik A, Dutta A. tRNA fragments (tRFs) guide ago to regulate gene expression post-transcriptionally in a dicer-independent manner. Rna. 2018;24(8):8093–105.
36. Yamasaki S, Ivanov P, Hu GF, Anderson P. Angiogenin cleaves tRNA and promotes stress-induced translational repression. J Cell Biol. 2009;185(1):35–42.
37. Li S, Shi X, Chen M, Xu N, Sun D, Bai R, et al. Angiogenin promotes colorectal cancer metastasis via tRNA production. Int J Cancer. 2019;145(5):1395–407.
38. Su Z, Kuscu C, Malik A, Shibata E, Dutta A. Angiogenin generates specific stress-induced tRNA halves and is not involved in tRF-3-mediated gene silencing. J Biol Chem. 2019;294(45):16930–41.
39. Schaefer M, Pollex T, Hanna K, Tuorto F, Meusburger M, Helm M, et al. RNA methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage. Genes Dev. 2010;24(15):1590–5.
40. Blanco S, Dietmann S, Flores JV, Hussain S, Kutter C, Humphreys P, et al. Aberrant methylation of tRNAs links cellular stress to neuro-developmental disorders. EMBO J. 2014;33(18):2020–39.
41. Rashad S, Han X, Sato K, Mishima E, Abe T, Tominaga T, et al. The stress specific impact of ALKBH1 on tRNA cleavage and tiRNA generation. RNA Biol. 2020:1–12.
42. Guzzi N, Ciesla M, Ngoc PCT, Lang S, Arora S, Dimitriou M, et al. Pseudouridylation of tRNA-derived fragments steers translational control in stem cells. Cell. 2018;173(5):1204–1216 e26.
43. Chen Z, Qi M, Shen B, Luo G, Wu Y, Li J, et al. Transfer RNA demethylation ALKBH3 promotes cancer progression via induction of tRNA-derived small RNAs. Nucleic Acids Res. 2019;47(5):2533–45.
44. Cozen AE, Quartley E, Holmes AD, Hrabeta-Robinson E, Phizicky EM, Lowe TM. ARM-seq: AlkB-facilitated RNA methylation sequencing reveals a complex landscape of modified tRNA fragments. Nat Methods. 2015;12(9):879–84.
45. Akiyama Y, Kharel P, Abe T, Anderson P, Ivanov P. Isolation and initial structure-functional characterization of endogenous tRNA-derived stress-induced RNAs. RNA Biol. 2020:1–9.
46. Lyons SM, Gudanis D, Coyne SM, Gdaniec Z, Ivanov P. Author correction: identification of functional tetramolecular RNA G-quadruplexes derived from transfer RNAs. Nat Commun. 2017;8(1):2020.
47. Lyons SM, Kharel P, Akiyama Y, Ojha S, Dave D, Tsvetkov V, et al. eIF4G has intrinsic G-quadruplex binding activity that is required for tiRNA function. Nucleic Acids Res. 2020;48(11):6223–33.
48. Balatti V, Nigita G, Veneziano D, Drusco A, Stein GS, Messier TL, et al. tiRNA signatures in cancer. Proc Natl Acad Sci U S A. 2017;114(30):8071–6.
49. Zhong F, Hu Z, Jiang K, Lei B, Wu Z, Yuan G, et al. Complement C3 activation regulates the production of tRNA-derived fragments Gly-tRFs and promotes alcohol-induced liver injury and steatosis. Cell Res. 2019;29(7):548–61.
50. Goncalves KA, Silberstein L, Li S, Severe N, Hu MG, Yang H, et al. Angiogenin promotes hematopoietic regeneration by dichotomously regulating quiescence of stem and progenitor cells. Cell. 2016;166(4):894–906.
51. Kishimoto K, Yoshida S, Ibaragi S, Yoshioka N, Okui T, Hu GF, et al. Hypoxia-induced up-regulation of angiogenin, besides VEGF, is related to progression of oral cancer. Oral Oncol. 2012;48(11):1120–7.
52. Sebastia J, Kieran D, Breen B, King MA, Netteland DF, Joyce D, et al. Angiogenin protects motoneurons against hypoxic injury. Cell Death Differ. 2000;6(9):1288–47.
53. Saikia M, Jobava R, Parisien M, Putnam A, Krokowski D, Gao XH, et al. Angiogenin-cleaved tRNA halves interact with cytochrome c, protecting cells from apoptosis during osmotic stress. Mol Cell Biol. 2014;34(13):2450–63.
54. Li S, Chen Y, Sun D, Bai R, Gao X, Yang Y, et al. Angiogenin prevents Programlin ASD mutation-induced neuronal-like cell apoptosis through cleaving tRNAs into tiRNAs. Mol Neurobiol. 2018;55(2):1338–51.
55. Ren B, Wang X, Duan J, Ma J. Rhizobial tRNA-derived small RNAs are signal molecules regulating plant nodule development. Science. 2019;365(6456):919–22.
56. Hansen CG, Ng YL, Lam WL, Plouffe SW, Guan KL. The hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1. Cell Res. 2015;25(12):1299–313.
57. Gao XW, Xu ZP. Mechanisms of action of angiogenin. Acta Bioch Bioph Sin. 2008;40(7):619–24.
58. Li Q, Hu B, Hu GW, Chen CY, Niu X, Liu J, et al. tRNA-derived small non-coding RNAs in response to ischemia inhibit angiogenesis. Sci Rep. 2016;6:20850.